Lamivudine

CHEMBL141 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
229.3 g/mol
LogP
-0.9
Phase
4

An antiretroviral nucleoside reverse transcriptase inhibitor used to treat HIV infection and chronic hepatitis B. It works by blocking the reverse transcriptase enzyme that HIV needs to replicate.

Molekularmasse

229,2600 g/mol

LogP

-0,90

TPSA

113,00 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1

InChI

InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

Molecular Formula

C8H11N3O3S

HBD / HBA

2 / 4

Rotierbare Bindungen

2

Schwere Atome

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An antiretroviral nucleoside reverse transcriptase inhibitor used to treat HIV infection and chronic hepatitis B. It works by blocking the reverse transcriptase enzyme that HIV needs to replicate.

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Yes, Lamivudine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL141. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60825. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.